First Time Loading...
S

Shandong Pharmaceutical Glass Co Ltd
SSE:600529

Watchlist Manager
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
Watchlist
Price: 28.35 CNY -1.25% Market Closed
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

9B
-0.5%
Assets
Growth Rates:
1 Year
+34%
3 Years
+66%
5 Years
+103%
7 Years
+184%
10 Years
+237%
1.6B
-14%
Liabilities
Growth Rates:
1 Year
-5%
3 Years
+24%
5 Years
+60%
7 Years
+92%
10 Years
+147%
7.4B
+3%
Equity
Growth Rates:
1 Year
+48%
3 Years
+80%
5 Years
+115%
7 Years
+218%
10 Years
+267%

Balance Sheet Decomposition
Shandong Pharmaceutical Glass Co Ltd

9B
Assets
1.6B
Liabilities
9B
Assets
1.6B
Liabilities
Current Assets 5.4B
Cash & Short-Term Investments 2.4B
Receivables 1.7B
Other Current Assets 1.2B
Non-Current Assets 3.7B
Long-Term Investments 50k
PP&E 2.9B
Intangibles 255.3m
Other Non-Current Assets 511m
Current Liabilities 1.6B
Accounts Payable 650.8m
Accrued Liabilities 18.3m
Short-Term Debt 586.9m
Other Current Liabilities 334m
Non-Current Liabilities 53.8m
Other Non-Current Liabilities 53.8m

Balance Sheet
Shandong Pharmaceutical Glass Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022
Assets
Cash & Cash Equivalents
149
227
313
1 078
714
717
923
1 010
708
1 160
Cash
0
0
0
0
0
0
0
0
708
1 160
Cash Equivalents
149
227
313
1 078
714
717
923
1 010
0
0
Short-Term Investments
29
67
85
180
728
788
462
231
307
1 101
Total Receivables
727
730
681
690
725
737
739
949
1 203
1 570
Accounts Receivables
407
424
391
436
389
384
405
641
764
872
Other Receivables
320
306
290
254
336
353
334
308
439
699
Inventory
487
475
531
512
545
571
679
749
878
1 210
Other Current Assets
25
28
22
43
38
179
200
206
239
279
Total Current Assets
1 417
1 526
1 631
2 503
2 750
2 992
3 003
3 144
3 335
5 321
PP&E Net
1 158
1 160
1 199
1 239
1 287
1 449
1 970
2 244
2 844
3 171
PP&E Gross
1 158
1 160
1 199
1 239
1 287
1 449
1 970
2 244
2 844
3 171
Accumulated Depreciation
681
805
877
958
1 025
1 050
1 028
1 101
1 244
1 451
Intangible Assets
80
82
89
99
113
153
172
203
198
260
Long-Term Investments
26
26
25
22
0
0
0
0
0
0
Other Long-Term Assets
25
24
29
41
31
29
25
30
32
32
Total Assets
2 706
N/A
2 818
+4%
2 973
+5%
3 904
+31%
4 180
+7%
4 624
+11%
5 170
+12%
5 621
+9%
6 410
+14%
8 784
+37%
Liabilities
Accounts Payable
242
230
315
318
336
385
564
505
722
696
Accrued Liabilities
4
7
18
22
28
43
45
99
69
51
Short-Term Debt
360
358
232
341
381
417
432
490
714
842
Other Current Liabilities
70
98
144
153
154
220
212
211
174
175
Total Current Liabilities
676
693
710
833
900
1 066
1 253
1 306
1 679
1 764
Long-Term Debt
0
0
0
0
0
0
0
0
0
0
Minority Interest
0
9
9
0
0
0
0
0
0
0
Other Liabilities
0
0
26
27
30
33
50
60
60
59
Total Liabilities
676
N/A
702
+4%
744
+6%
861
+16%
930
+8%
1 098
+18%
1 303
+19%
1 366
+5%
1 739
+27%
1 823
+5%
Equity
Common Stock
257
257
257
304
304
425
595
595
595
664
Retained Earnings
1 186
1 272
1 385
1 535
1 742
2 017
2 359
2 748
3 162
3 611
Additional Paid In Capital
587
587
587
1 205
1 205
1 083
913
913
913
2 687
Total Equity
2 030
N/A
2 116
+4%
2 229
+5%
3 044
+37%
3 250
+7%
3 526
+8%
3 868
+10%
4 256
+10%
4 670
+10%
6 962
+49%
Total Liabilities & Equity
2 706
N/A
2 818
+4%
2 973
+5%
3 904
+31%
4 180
+7%
4 624
+11%
5 170
+12%
5 621
+9%
6 410
+14%
8 784
+37%
Shares Outstanding
Common Shares Outstanding
505
505
505
595
595
595
595
595
595
664

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.